183 related articles for article (PubMed ID: 33974127)
21. Reduced p21(WAF1/CIP1) via alteration of p53-DDX3 pathway is associated with poor relapse-free survival in early-stage human papillomavirus-associated lung cancer.
Wu DW; Liu WS; Wang J; Chen CY; Cheng YW; Lee H
Clin Cancer Res; 2011 Apr; 17(7):1895-905. PubMed ID: 21325288
[TBL] [Abstract][Full Text] [Related]
22. Expression of androgen receptor and its phosphorylated forms in breast cancer progression.
Ren Q; Zhang L; Ruoff R; Ha S; Wang J; Jain S; Reuter V; Gerald W; Giri DD; Melamed J; Garabedian MJ; Lee P; Logan SK
Cancer; 2013 Jul; 119(14):2532-40. PubMed ID: 23605249
[TBL] [Abstract][Full Text] [Related]
23. DDX3 RNA helicase is required for HIV-1 Tat function.
Yasuda-Inoue M; Kuroki M; Ariumi Y
Biochem Biophys Res Commun; 2013 Nov; 441(3):607-11. PubMed ID: 24183723
[TBL] [Abstract][Full Text] [Related]
24. Prognostic value of nuclear hepatoma-derived growth factor (HDGF) localization in patients with breast cancer.
Chen X; Yun J; Fei F; Yi J; Tian R; Li S; Gan X
Pathol Res Pract; 2012 Aug; 208(8):437-43. PubMed ID: 22682760
[TBL] [Abstract][Full Text] [Related]
25. Androgen receptor expression in male breast cancer predicts inferior outcome and poor response to tamoxifen treatment.
Wenhui Z; Shuo L; Dabei T; Ying P; Zhipeng W; Lei Z; Xiaohui H; Jingshu G; Hongtao S; Qingyuan Z
Eur J Endocrinol; 2014 Oct; 171(4):527-33. PubMed ID: 25069458
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of mitotic index and Bcl2 expression in male breast cancer.
Lacle MM; van der Pol C; Witkamp A; van der Wall E; van Diest PJ
PLoS One; 2013; 8(4):e60138. PubMed ID: 23573235
[TBL] [Abstract][Full Text] [Related]
27. Male breast cancer: Looking for better prognostic subgroups.
Abreu MH; Afonso N; Abreu PH; Menezes F; Lopes P; Henrique R; Pereira D; Lopes C
Breast; 2016 Apr; 26():18-24. PubMed ID: 27017238
[TBL] [Abstract][Full Text] [Related]
28. Male breast cancer in the veterans affairs population: a comparative analysis.
Nahleh ZA; Srikantiah R; Safa M; Jazieh AR; Muhleman A; Komrokji R
Cancer; 2007 Apr; 109(8):1471-7. PubMed ID: 17342768
[TBL] [Abstract][Full Text] [Related]
29. Nuclear DDX3 expression predicts poor outcome in colorectal and breast cancer.
Heerma van Voss MR; Vesuna F; Bol GM; Meeldijk J; Raman A; Offerhaus GJ; Buerger H; Patel AH; van der Wall E; van Diest PJ; Raman V
Onco Targets Ther; 2017; 10():3501-3513. PubMed ID: 28761359
[TBL] [Abstract][Full Text] [Related]
30. NZ51, a ring-expanded nucleoside analog, inhibits motility and viability of breast cancer cells by targeting the RNA helicase DDX3.
Xie M; Vesuna F; Botlagunta M; Bol GM; Irving A; Bergman Y; Hosmane RS; Kato Y; Winnard PT; Raman V
Oncotarget; 2015 Oct; 6(30):29901-13. PubMed ID: 26337079
[TBL] [Abstract][Full Text] [Related]
31. DEAD-box RNA Helicase DDX3: Functional Properties and Development of DDX3 Inhibitors as Antiviral and Anticancer Drugs.
Kukhanova MK; Karpenko IL; Ivanov AV
Molecules; 2020 Feb; 25(4):. PubMed ID: 32102413
[TBL] [Abstract][Full Text] [Related]
32. Tracing differences between male and female breast cancer: both diseases own a different biology.
Kornegoor R; van Diest PJ; Buerger H; Korsching E
Histopathology; 2015 Dec; 67(6):888-97. PubMed ID: 25941088
[TBL] [Abstract][Full Text] [Related]
33. The Clinical and Pathological Significance of Nectin-2 and DDX3 Expression in Pancreatic Ductal Adenocarcinomas.
Liang S; Yang Z; Li D; Miao X; Yang L; Zou Q; Yuan Y
Dis Markers; 2015; 2015():379568. PubMed ID: 26294807
[TBL] [Abstract][Full Text] [Related]
34. A Prognostic Analysis of Male Breast Cancer (MBC) Compared with Post-Menopausal Female Breast Cancer (FBC).
Yu XF; Yang HJ; Yu Y; Zou DH; Miao LL
PLoS One; 2015; 10(8):e0136670. PubMed ID: 26313461
[TBL] [Abstract][Full Text] [Related]
35. A Case-Matched Gender Comparison Transcriptomic Screen Identifies eIF4E and eIF5 as Potential Prognostic Markers in Male Breast Cancer.
Humphries MP; Sundara Rajan S; Droop A; Suleman CAB; Carbone C; Nilsson C; Honarpisheh H; Cserni G; Dent J; Fulford L; Jordan LB; Jones JL; Kanthan R; Litwiniuk M; Di Benedetto A; Mottolese M; Provenzano E; Shousha S; Stephens M; Walker RA; Kulka J; Ellis IO; Jeffery M; Thygesen HH; Cappelletti V; Daidone MG; Hedenfalk IA; Fjällskog ML; Melisi D; Stead LF; Shaaban AM; Speirs V
Clin Cancer Res; 2017 May; 23(10):2575-2583. PubMed ID: 27986751
[No Abstract] [Full Text] [Related]
36. Expression of connective tissue growth factor in male breast cancer: clinicopathologic correlations and prognostic value.
Lacle MM; van Diest PJ; Goldschmeding R; van der Wall E; Nguyen TQ
PLoS One; 2015; 10(3):e0118957. PubMed ID: 25738829
[TBL] [Abstract][Full Text] [Related]
37. Comparative study of two androgen-induced markers (apolipoprotein D and pepsinogen C) in female and male breast carcinoma.
Serra C; Vizoso F; Lamelas ML; Rodríguez JC; González LO; Merino AM; Baltasar A; Pérez-Vázquez MT; Medrano J
Int J Surg Investig; 2000; 2(3):183-92. PubMed ID: 12678518
[TBL] [Abstract][Full Text] [Related]
38. The Ded1/DDX3 subfamily of DEAD-box RNA helicases.
Sharma D; Jankowsky E
Crit Rev Biochem Mol Biol; 2014; 49(4):343-60. PubMed ID: 25039764
[TBL] [Abstract][Full Text] [Related]
39. Forkhead box M1 (FOXM1) expression predicts disease free survival and may mediate resistance to chemotherapy and hormonotherapy in male breast cancer.
Abdeljaoued S; Bettaieb L; Nasri M; Adouni O; Goucha A; Bouzaiene H; Boussen H; Rahal K; Gamoudi A
Breast Dis; 2018; 37(3):109-114. PubMed ID: 29504520
[TBL] [Abstract][Full Text] [Related]
40. The expression of calpain-1 and androgen receptor in breast cancer and their correlation with clinicopathological characteristics: An immunohistochemical retrospective study.
Rajković-Molek K; Mustać E; Avirović M; Georgev P; Demaria M; Aničić J; Ban J; Babarović E
Pathol Res Pract; 2020 Sep; 216(9):153068. PubMed ID: 32825941
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
